Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Seamless, Sequential Phase III, Randomized, Multi Center Single Blind Study to Evaluate Immunogenicity, Safety, Reactogenicity of Liquid ROTAVAC 5C Vaccine as a 3-dose Series When Compared With ROTAVAC® in Infants

NCT04819412 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT04819412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04819412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Seamless, Sequential Phase III, Randomized, Multi Center Single Blind Study to Evaluate Immunogenicity, Safety, Reactogenicity of Liquid ROTAVAC 5C Vaccine as a 3-dose Series When Compared With ROTAVAC® in Infants
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2015
Completion date
December 30, 2016
Enrollment
1,975 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rotavirus gastroenteritis